A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Certolizumab pegol (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CIMPACT
  • Sponsors UCB
  • Most Recent Events

    • 25 Jul 2017 According to an UCB media release, based on the data from CIMPASI-1 CIMPASI-2 and CIMPACT studies, an sBLA to the US FDA and a regulatory filing with the EMA has been submitted to expand the approved indications for certolizumab pegol to include treatment of adult patients with moderate-to-severe chronic plaque psoriasis.An additional submission to expand the use of CIMZIA in this patient population is also planned with Health Canada.
    • 17 Mar 2017 According to a Dermira media release, additional data from this trial will be presented at 13th Annual Maui Derm for Dermatologists 2017 meeting.
    • 19 Jan 2017 Results published in the UCB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top